A dreaded patent cliff is looming for a number of key drugs positioned to topple over to the other side. 

Some of pharma’s biggest wallops are still a few years off, such as the loss of a critical patent for Merck & Co.’s Keytruda in 2028. Other companies, like Pfizer, face a steady stream of blows as exclusivity for top-selling drugs fades away each year. 

At AstraZeneca, two major losses are just months away. Before the year is out, the company will lose its market grip on Soliris, a rare disease drug, and Farxiga, a heart and diabetes medication, which pulled in over $10 billion in revenue last year combined. 

Scoring new approvals will be critical to filling the gaps left by these blockbusters. So far this year, AstraZeneca is on a roll with its Daiichi Sankyo-partnered antibody-drug conjugates — a key component of its lofty goal to hit $80 billion in annual revenue by 2030. Today, we’re looking more closely at these FDA nods along with other standout drugs that recently crossed the regulatory finish line. 

Thanks for reading.